Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0032
Investigational oncology
CB-839 / Telaglenastat
Senolytic / GLS1
GLS1-dependent senolysis positioning; oncology metabolism research
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Glutaminase-1 inhibition
- Primary market use
- Senolytic / oncology metabolism
Pharmacology
- Molecular weight (Da)
- 571.5
- Oral bioavailability
- Oral; human F not publicly clear
- Half-life
- ~4 h
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical/Preclinical
- Clinical status
- Investigational oncology
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
More clinically developed GLS1 inhibitor; senolytic use remains indirect/preclinical